Stock TENAX THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Tenax Therapeutics Inc Nasdaq

Equities

US88032L1008

Biotechnology & Medical Research

Business Summary

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Managers

Managers TitleAgeSince
Christopher Giordano CEO
 Chief Executive Officer 50 13/07/21
Lawrence R. Hoffman DFI
 Director of Finance/CFO 69 01-10
Stuart Rich CTO
 Chief Tech/Sci/R&D Officer 74 14/01/21
Doug Randall COO
 Chief Operating Officer - 13/11/13
Douglas Hay LAW
 General Counsel - 13/11/13

Members of the board

Members of the board TitleAgeSince
Gerry Proehl CHM
 Chairman 65 03/04/14
June Almenoff BRD
 Director/Board Member 67 24/02/21
Declan Doogan BRD
 Director/Board Member 72 24/02/21
Michael Davidson BRD
 Director/Board Member 67 24/02/21
Robyn Hunter BRD
 Director/Board Member 62 27/01/22
Stuart Rich CTO
 Chief Tech/Sci/R&D Officer 74 14/01/21
Christopher Giordano CEO
 Chief Executive Officer 50 13/07/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 210 0 0 99.65 %
Stock B 1 1,958,245 1,951,297 ( 99.65 %) 0

Shareholders

NameEquities%Valuation
Heights Capital Management, Inc.
10.42 %
204,027 10.42 % 734 497 $
S.H.N. Financial Investments Ltd.
5.464 %
107,000 5.464 % 385 200 $
The Lind Partners LLC
3.651 %
71,500 3.651 % 257 400 $
Qube Research & Technologies Ltd. (France)
0.2250 %
4,407 0.2250 % 15 865 $
Stuart Rich
0.1355 %
2,654 0.1355 % 9 554 $
Declan Doogan
0.1161 %
2,274 0.1161 % 8 186 $
Intracoastal Capital LLC
0.0836 %
1,637 0.0836 % 5 893 $
UBS Securities LLC
0.0707 %
1,384 0.0707 % 4 982 $
Tower Research Capital LLC
0.0274 %
537 0.0274 % 1 933 $
Michael Davidson
0.0194 %
380 0.0194 % 1 368 $

Company contact information

Tenax Therapeutics, Inc.

101 Glen Lennox Drive Suite 300

27517, Chapel Hill

+(919) 855-2100

http://www.tenaxthera.com
address Tenax Therapeutics Inc

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TENX Stock
  4. Stock
  5. Company Tenax Therapeutics Inc